Health Care Contact Days Experienced by Decedents With Advanced GI Cancer
Overview
Authors
Affiliations
Purpose: Frequent visits to health care facilities can be time intensive and all-consuming for people with cancer. We measured health care contact days (days with healthcare contact outside the home) among decedents with advanced GI cancer and examined sources of contact days, their associations with demographic and clinical factors, and their temporal patterns over the course of illness.
Methods: We conducted a retrospective cohort study using a tumor registry and electronic medical record data for decedents with stage IV GI cancer between 2011 and 2019 in a large health care network in MN. We determined contact days from diagnosis to death using chart review. Using multivariable beta regression adjusted for sociodemographic and clinical characteristics offset by survival, we calculated adjusted estimates of contact days and determined patient-level factors associated with percentage of contact days.
Results: We identified 809 patients eligible for analysis (median [IQR] age at diagnosis, 65 [56-73] years). The median (IQR) overall survival was 175 (56-459) days. Patients spent a median (IQR) of 25.8% (17.4%-39.1%) of these as contact days. Of these days, 83.6% were spent on outpatient visits. In the multivariable analysis, older age, Black race, and never receiving systemic cancer-directed treatment were associated with a higher percentage of contact days. The percentage of contact days was highest in the first month after diagnosis (39.6%) and before death (32.2%), with a more moderate middle phase (U-shaped curve).
Conclusion: Decedents with advanced GI cancer spend 1 in 4 days alive with health care contact, despite a median survival of under 6 months. This is even higher immediately postdiagnosis and near death. These findings highlight the need to understand sources of variation, benchmark appropriate care, and deliver more efficient care for this vulnerable population with limited time.
Time's up: the urgency to investigate time toxicity in patients with genitourinary malignancies.
Sentana-Lledo D, Morgans A Ther Adv Med Oncol. 2024; 16:17588359241305088.
PMID: 39664299 PMC: 11632889. DOI: 10.1177/17588359241305088.
Time toxicity among older patients with cancer treated with palliative systemic therapy.
Baltussen J, Cardenas-Reyes P, Chavarri-Guerra Y, Ramirez-Fontes A, Morales-Alfaro A, Portielje J Support Care Cancer. 2024; 32(9):621.
PMID: 39212749 DOI: 10.1007/s00520-024-08844-1.
Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit.
Gupta A, Brundage M, Galica J, Karim S, Koven R, Ng T Oncologist. 2024; 29(11):978-985.
PMID: 39045654 PMC: 11546709. DOI: 10.1093/oncolo/oyae187.
Trajectories of Health Care Contact Days for Patients With Stage IV Non-Small Cell Lung Cancer.
Gupta A, Nguyen P, Kain D, Robinson A, Kulkarni A, Johnson D JAMA Netw Open. 2024; 7(4):e244278.
PMID: 38587847 PMC: 11002696. DOI: 10.1001/jamanetworkopen.2024.4278.
Health Care Contact Days Among Older Cancer Survivors.
Gupta A, Chant E, Mohile S, Vogel R, Parsons H, Blaes A JCO Oncol Pract. 2024; 20(7):943-952.
PMID: 38452315 PMC: 11268556. DOI: 10.1200/OP.23.00590.